ARS Pharmaceuticals, Inc. (SPRY) stock
Close on Nov 13, 2026Market cap $386.85MP/E –Yield –
Earnings
ARS Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of ARS Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 8, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $37.70M | +16.0% | -$0.36 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026after the close | $33.70M | – | -$0.63 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 15, 2026before the open | $22.70M | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 9, 2026before the open | $28.10M | -67.6% | $0.42 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | $32.50M | +1447.6% | -$0.52 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025before the open | – | – | -$0.46 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 20, 2025before the open | $86.60M | – | $0.48 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024before the open | $2.10M | – | -$0.20 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024after the close | $500.00K | +4900.0% | -$0.13 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | – | – | -$0.11 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 21, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | – | – | -$0.16 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023after the close | $10.00K | – | -$0.18 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023before the open | $20.00K | – | -$0.16 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 23, 2023after the close | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022after the close | – | – | -$0.70 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 31, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021after the close | – | – | -$0.65 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 29, 2021after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
ARS Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| aggregate SG&A and R&D expenses | FY2026 | $114.00M – $126.00M | – | New | Aug 13, 2026 |
| aggregate SG&A and R&D expenses, including stock-based compensation | FY2026 | $114.00M – $126.00M | – | Raised | Nov 5, 2026 |
| stock-based compensation expense | FY2026 | $14.00M – $16.00M | – | Lowered | Aug 13, 2026 |
| total cash-based SG&A and R&D expensesnon-GAAP | FY2026 | $100.00M – $110.00M | – | New | Aug 13, 2026 |
Guidance history
Every forecast ARS Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | aggregate SG&A and R&D expenses, including stock-based compensation | FY2026 | $114.00M – $126.00M | Raised |
| Aug 13, 2026 | aggregate SG&A and R&D expenses | FY2026 | $114.00M – $126.00M | New |
| Aug 13, 2026 | stock-based compensation expense | FY2026 | $14.00M – $16.00M | Lowered |
| Aug 13, 2026 | total cash-based SG&A and R&D expenses | FY2026 | $100.00M – $110.00M | New |
| Nov 10, 2025 | gross-to-net retention | steady-state | 50% | – |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases ARS Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?